We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
Cap. Flow
+$217M
Cap. Flow %
8.29%
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$64.1M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$36.1M
3
XLRN
Acceleron Pharma
XLRN
+$31.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$17.7M
5
CBAY
Cymabay Therapeutics
CBAY
+$15.9M

Top Sells

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$42.4M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$36.7M
3
RDUS
Radius Health, Inc.
RDUS
+$29.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$20.9M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.22%
2 Industrials 0.33%
3 Consumer Staples 0.16%
4 Consumer Discretionary 0.07%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOK
26
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$23.6M 0.9%
550,717
-2,437
-0.4% -$77.7K
ALDX icon
27
Aldeyra Therapeutics
ALDX
$93.5M
$22.2M 0.85%
3,085,458
+200,000
+7% +$1.04M
BOLD
28
DELISTED
Audentes Therapeutics, Inc
BOLD
$21.9M 0.84%
781,309
+73,809
+10% +$1.6M
RNAC icon
29
Cartesian Therapeutics
RNAC
$314M
$21.2M 0.81%
38,744
+12,166
+46% +$6.47M
VRTX icon
30
Vertex Pharmaceuticals
VRTX
$140B
$21.1M 0.81%
138,626
-138,726
-50% -$20.9M
LKFT
31
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.94B
$21M 0.8%
206,405
-20,000
-9% -$1.75M
IRTC icon
32
iRhythm Holdings
IRTC
$4.06B
$19.3M 0.74%
372,671
+89,814
+32% +$4.07M
CBAY
33
DELISTED
Cymabay Therapeutics
CBAY
$18.9M 0.72%
+2,350,882
New +$15.9M
QTNT
34
DELISTED
Quotient Limited Ordinary Shares
QTNT
$18.4M 0.7%
93,175
+313
+0.3% +$62.5K
ALBO
35
DELISTED
Albireo Pharma Inc
ALBO
$17.7M 0.68%
845,000
– –
NVTA
36
DELISTED
Invitae Corporation
NVTA
$17.7M 0.67%
1,884,500
+1,235,000
+190% +$11.7M
KDMN
37
DELISTED
Kadmon Holdings, Inc.
KDMN
$17.4M 0.66%
5,185,847
– –
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
$16.3M 0.62%
1,549,005
+119,891
+8% +$1.14M
ONCE
39
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$16M 0.61%
+180,000
New +$13.7M
ABEOW
40
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$15.8M 0.61%
1,259,636
– –
ADYX
41
DELISTED
Adynxx Inc
ADYX
$15.5M 0.59%
70,566
– –
ASMB icon
42
Assembly Biosciences
ASMB
$719M
$15.4M 0.59%
36,819
– –
EVH icon
43
Evolent Health
EVH
$553M
$15.1M 0.58%
850,000
-224,327
-21% -$4.62M
ITCI
44
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$14.7M 0.56%
+929,460
New +$13.6M
ATRS
45
DELISTED
Antares Pharma, Inc.
ATRS
$14.1M 0.54%
4,353,897
+86,644
+2% +$267K
WVE icon
46
Wave Life Sciences
WVE
$1.03B
$14M 0.53%
642,798
-20,000
-3% -$402K
TFX icon
47
Teleflex
TFX
$5.94B
$13.4M 0.51%
+55,200
New +$12M
SYBX
48
DELISTED
Synlogic
SYBX
$13.1M 0.5%
+45,757
New +$9.36M
AVEO
49
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$12.6M 0.48%
341,512
-259,554
-43% -$8.03M
BHVN
50
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$11.4M 0.44%
306,134
+186,134
+155% +$5.65M
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors deployed $217M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.

  • Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
  • Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
  • Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
  • Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
  • Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.

Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.